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Molecular psychiatry is a still nascent ﬁ  eld, 
aspiring to imitate the great development of 
revolutionary tools and techniques achieved 
elsewhere. The rapid development of new 
methods such as high-throughput genomic 
and bioinformatics technologies has greatly 
advance our understanding of the pathol-
ogy and etiology of most, if not all, psychi-
atric disorders, far beyond what we would 
have expected a few years ago.
Although these great advances have 
brought us closer to understanding the 
development of many psychiatric dis-
orders, the majority of the questions 
about their origins remain. Many of these 
questions are not only of great scientiﬁ  c 
importance but also of broad interest to 
the rest of society and the general public. 
As reported recently by the World Health 
Organization (2008), disorders of the 
nervous system affect hundreds of mil-
lions of people worldwide. For example, 
depression affects 154 million people, 25 
million people suffer from schizophrenia, 
91 million people are affected by alcohol 
use disorders, 15 million people suffer 
from drug use disorders, epilepsy impacts 
50 million, and 24 million people suffer 
from Alzheimer’s disease or other demen-
tias. The collective burden of these disor-
ders has a signiﬁ  cant impact on the world’s 
economic output.
The primary missions of research in 
molecular psychiatry are, ﬁ  rst, to under-
stand the mechanisms underlying the devel-
opment of these psychiatric disorders at the 
molecular level and then to ﬁ  nd ways to pre-
vent and treat them more effectively. Such 
broad missions determine that molecular 
psychiatry is not a single science but rather 
a multidisciplinary enterprise including 
diverse ﬁ  elds such as molecular biology and 
genetics, psychology and psychiatry, neurol-
ogy, pharmacology, chemistry, biostatistics 
and bioinformatics, and engineering and 
computer sciences. Our past successes – in 
combination with the revolutionary new 
tools and technologies from molecular 
biology and genetics, information science 
and technology, mathematics, bioinformat-
ics, and neuroimaging – have positioned 
molecular psychiatry on the cusp of even 
greater transformational progress in our 
understanding of the brain and how its 
actions result in mental activities and vari-
ous disorders of the nervous system.
For decades, philosophers and scien-
tists have argued about the inﬂ  uences of 
nurture (or biological inheritance) ver-
sus nature. As our understanding of the 
brain has advanced, it has become clear 
that what really matters is the interplay 
between nature and nurture. To the best 
of our knowledge, almost all common psy-
chiatric disorders such as schizophrenia, 
bipolar disorder, Alzheimer’s disease, and 
addiction are complex genetic disorders 
inﬂ  uenced by both biologic and environ-
mental factors as well as their interactions. 
There is no doubt that the ﬁ  elds of psy-
chiatry and other nervous system disor-
ders have beneﬁ   ted tremendously from 
better understanding of the role of genet-
ics. However, genes do not equate with 
destiny. Not only does the environment 
impact the development of these complex 
psychiatric disorders, but genetics as well. 
With an improved understanding of brain 
functions; i.e., the brain’s ability to shape, 
form, eliminate, and strengthen different 
neuronal networks and circuitries, we can 
begin to understand how brain structure 
and function continue to change through-
out our lives. What we do in brain research, 
more speciﬁ  cally in molecular psychiatry, is 
to determine which genes and variants are 
involved and how they are expressed over 
different developmental stages or interact 
with environmental factors to shape each 
person’s life. To attack these daunting but 
important tasks, there exist many chal-
lenges, which can be summarized brieﬂ  y 
as follows.
The ﬁ  rst challenge is to determine which 
genes and, speciﬁ  cally, which variants con-
tribute to the development of a psychiatric 
disorder. Although this effort with either 
candidate gene-based or a genome-wide 
association (GWA) study has continued for 
years and has identiﬁ  ed numerous genes for 
each disorder, only a few of them have been 
replicated in independent samples, in which 
small sample size (especially for earlier stud-
ies) and heterogeneity in deﬁ  ning each phe-
notype and outcome measure might have 
contributed greatly to this problem. To 
address those concerns, we must increase 
our sample size through pooled approach 
or meta-analysis of multiple independent 
  samples reduce potential heterogeneity 
among the samples by using intermediate 
phenotypes such as endophenotypes, her-
itable biochemical or neurophysiological 
markers (i.e., determined by genes), and 
objective measures (i.e., less inﬂ  uenced by 
behavioral factors or biased by each investi-
gator). On the other hand, we need to realize 
that sample size can only change the ﬁ  nal 
P-value for our results from the association 
test and has no impact on the effect size of 
each genetic variant under investigation. In 
other words, we should not be fooled by 
ﬁ  nal P values and must have a proper bal-
ance between sample size (power) and the 
cost of subject recruitment, genotyping, and 
statistical analysis. Although we all agree 
that GWA has been relatively successful in 
ﬁ  nding genetic variants responsible for a 
psychiatric disease, with the identiﬁ  cation 
of variants in the nicotinic receptor subunit 
genes cluster on chromosome 15 that are 
important for smoking dependence and 
lung cancer being one of the most success-
ful examples (e.g., Amos et al., 2008; Hung 
et al., 2008; Thorgeirsson et al., 2008), there 
exist various limitations of this powerful 
approach. Because of the concern about 
false positives that may result from such 
a high-throughout approach, a stringent 
threshold for genome-wide signiﬁ  cance 
level must be adopted, in which only a few 
genetic markers can survive correction for 
multiple testing, a number that appears to 
be far less than we would expect according Frontiers in Psychiatry | Molecular Psychiatry    January 2010  | Volume 1  |  Article 2  |  2
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expression studies based on  microarray and 
RNA sequencing, genome-wide studies of 
changes in methylation and histones, and 
targeted deep sequencing for both SNPs 
and CNVs of whole genome or candidate 
genes implicated in psychiatric illnesses. 
Unfortunately, only a few research labo-
ratories are staffed and equipped for such 
challenges in both hardware and software. 
To face such challenges, we need active col-
laborations among molecular biologists, 
biostatisticians, and computer scientists 
to ﬁ  nd effective means/tools, not only to 
manage the data, but also to analyze and 
interpret them.
In sum, we have made signiﬁ  cant progress 
toward our goals; however, we still have long 
way to go. Yes, these are challenges but also 
opportunities. Much work needs to be done, 
not only to determine which genetic vari-
ants are involved and how they are engaged 
through what mechanisms but also how to 
translate these basic science advances into 
new therapeutic options for the prevention 
and treatment of psychiatric disorders.
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